Shanghai Changzheng Hospital
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1955-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.shczyy.com
Clinical Trials
117
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (97 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of Rifaximin in Treating MAFLD
- Conditions
- Metabolic-associated Fatty Liver Disease
- Interventions
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT07185932
- Locations
- 🇨🇳
Changzheng Hospital, Naval Medical University, shanghai, China, Shanghai, Shanghai Municipality, China
Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO
- Conditions
- Thyroid Associated Ophthalmopathies
- Interventions
- Other: Follew-up
- First Posted Date
- 2025-09-03
- Last Posted Date
- 2025-09-03
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT07152392
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai Municipality, China
Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.
- Conditions
- Thyroid Associated Ophthalmopathies
- Interventions
- Drug: Glucocorticoids
- First Posted Date
- 2025-09-03
- Last Posted Date
- 2025-09-03
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 96
- Registration Number
- NCT07152366
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai Municipality, China
The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.
- Conditions
- Thyroid Associated Ophthalmopathies
- Interventions
- Drug: Glucocorticoids
- First Posted Date
- 2025-09-03
- Last Posted Date
- 2025-09-03
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 64
- Registration Number
- NCT07152340
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai Municipality, China
Observational Study of Sacral Nerve Function After Sacral Tumor Resection
- Conditions
- Sacral Tumors
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT07105644
- Locations
- 🇨🇳
Changzheng Hospital, Shanghai, Shanghai, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 23
- Next
News
First-in-Human iPSC-CAR-NK Cell Therapy Shows Promise for Autoimmune Disease Treatment
Qihan Biotech's QN-139b represents the first-ever application of iPSC-CAR-NK cells in treating autoimmune disease, successfully inducing immune reset in a patient with refractory systemic sclerosis.